LIR Life Sciences Launches Phase 2 Peptide Design with Neuland to Boost Transdermal Therapies

LIR Life Sciences Corp. Commences Phase 2 of Peptide Design Program with Neuland Laboratories

LIR Life Sciences Corp. (CSE: SKNY, OTC PINK: BBCMF, Frankfurt: N790, WKN: A41QA9) announced on 5 February 2026 that it has entered the second phase of its peptide‑design collaboration with Neuland Laboratories Limited. The announcement was issued through a press release distributed via ACCESS Newswire and reported by multiple financial‑news outlets, including Finanznachrichten.de, Onvista, Wallstreet‑Online.de, and theCSE.com.

Background of the Collaboration

Existing Services Agreement: The partnership is governed by a services agreement signed on 8 January 2026.
Phase 1 Outcomes: Phase 1 of the program, focused on peptide synthesis, concluded successfully.
Phase 2 Objectives: The current program centers on the design and optimisation of next‑generation cell‑penetrating peptides that are intended to enhance LIR’s transdermal delivery platform.

Technical Focus

Phase 2 involves systematic structure‑activity‑relationship studies to refine peptide properties such as cellular uptake efficiency, stability, and skin permeability. The goal is to produce peptides that can effectively traverse the skin barrier, thereby supporting LIR’s broader therapeutic delivery strategy.

Company Context

Market Listing: The company trades on the Canadian National Stock Exchange (CSE) under the ticker SKNY and on the OTC Pink market under the symbol BBCMF.
Financial Snapshot (as of 3 February 2026):
Close price: 1.69 CAD
52‑week high: 2.41 CAD (1 January 2026)
52‑week low: 0.30 CAD (14 August 2025)
Market capitalisation: ≈ 50.7 million CAD

Strategic Implications

The progression to Phase 2 indicates that LIR is advancing its pipeline toward translational application, with a specific focus on non‑invasive delivery technologies. Successful development of these peptides could position the company as a provider of novel transdermal therapeutics, potentially expanding its market footprint within the biopharmaceutical sector.